Victoria Castel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4211377/publications.pdf

Version: 2024-02-01

58 papers	6,106 citations	201674 27 h-index	133252 59 g-index
61 all docs	61 docs citations	61 times ranked	4807 citing authors

#	Article	IF	Citations
1	Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.. Journal of Clinical Oncology, 1993, 11, 1466-1477.	1.6	1,997
2	The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report. Journal of Clinical Oncology, 2009, 27, 289-297.	1.6	1,540
3	Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncology, The, 2017, 18, 500-514.	10.7	256
4	Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 1617-1629.	10.7	252
5	Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project. Journal of Clinical Oncology, 2011, 29, 3286-3292.	1.6	248
6	Excellent Outcome With Reduced Treatment for Infants With Disseminated Neuroblastoma Without MYCN Gene Amplification. Journal of Clinical Oncology, 2009, 27, 1034-1040.	1.6	134
7	Poor Survival for Infants With MYCN-Amplified Metastatic Neuroblastoma Despite Intensified Treatment: The International Society of Paediatric Oncology European Neuroblastoma Experience. Journal of Clinical Oncology, 2009, 27, 1014-1019.	1.6	123
8	Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study. Journal of Clinical Oncology, 2010, 28, 3516-3524.	1.6	114
9	Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group. British Journal of Cancer, 2008, 99, 1027-1033.	6.4	110
10	28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures. Bone Marrow Transplantation, 2008, 41, S118-S127.	2.4	88
11	Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1). Cancers, 2020, 12, 309.	3.7	84
12	Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	6.4	82
13	The role of surgery in stage IV neuroblastoma. Journal of Pediatric Surgery, 2002, 37, 1574-1578.	1.6	80
14	Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study. Journal of Clinical Oncology, 2020, 38, 2902-2915.	1.6	60
15	Outcome of high-risk neuroblastoma using a dose intensity approach: Improvement in initial but not in long-term results. Medical and Pediatric Oncology, 2001, 37, 537-542.	1.0	48
16	Extracellular matrix composition defines an ultra-high-risk group of neuroblastoma within the high-risk patient cohort. British Journal of Cancer, 2016, 115, 480-489.	6.4	46
17	Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study. Cancer Research and Treatment, 2018, 50, 148-155.	3.0	46
18	Molecular biology of neuroblastoma. Clinical and Translational Oncology, 2007, 9, 478-483.	2.4	42

#	Article	IF	Citations
19	Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study. Journal of Clinical Oncology, 2021, 39, 2552-2563.	1.6	42
20	The Doublecortin Gene, A New Molecular Marker to Detect Minimal Residual Disease in Neuroblastoma. Diagnostic Molecular Pathology, 2005, 14, 53-57.	2.1	41
21	Surgical treatment for neuroblastoma: Complications during 15 years' experience. Journal of Pediatric Surgery, 1998, 33, 1526-1530.	1.6	38
22	Advances in emerging drugs for the treatment of neuroblastoma. Expert Opinion on Emerging Drugs, 2017, 22, 63-75.	2.4	36
23	Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 410-420.	2.8	35
24	Genetic Instability and Intratumoral Heterogeneity in Neuroblastoma with MYCN Amplification Plus 11q Deletion. PLoS ONE, 2013, 8, e53740.	2.5	33
25	Prospective evaluation of the International Neuroblastoma Staging System (INSS) and the International Neuroblastoma Response Criteria (INRC) in a multicentre setting. European Journal of Cancer, 1999, 35, 606-611.	2.8	32
26	MYCN gain and MYCN amplification in a stage 4S neuroblastoma. Cancer Genetics and Cytogenetics, 2003, 140, 157-161.	1.0	30
27	Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1). Journal of Clinical Oncology, 2021, 39, 3377-3390.	1.6	30
28	Neuroblastoma in adolescents: genetic and clinical characterisation. Clinical and Translational Oncology, 2010, 12, 49-54.	2.4	28
29	TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients. Journal of Cancer Research and Clinical Oncology, 2016, 142, 573-580.	2.5	28
30	Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study. British Journal of Cancer, 2018, 118, 1502-1512.	6.4	28
31	Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors. Oncogene, 2016, 35, 1423-1432.	5.9	27
32	Neuroblastoma after Childhood: Prognostic Relevance of Segmental Chromosome Aberrations, ATRX Protein Status, and Immune Cell Infiltration. Neoplasia, 2014, 16, 471-480.	5.3	25
33	Treatment of stage III neuroblastoma with emphasis on intensive induction chemotherapy: A report from the neuroblastoma group of the spanish society of pediatric oncology. Medical and Pediatric Oncology, 1995, 24, 29-35.	1.0	23
34	Emerging drugs for neuroblastoma. Expert Opinion on Emerging Drugs, 2013, 18, 155-171.	2.4	22
35	Vascular patterns provide therapeutic targets in aggressive neuroblastic tumors. Oncotarget, 2016, 7, 19935-19947.	1.8	22
36	Treatment of high-risk neuroblastoma with anti-GD2 antibodies. Clinical and Translational Oncology, 2010, 12, 788-793.	2.4	20

#	Article	IF	Citations
37	Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1263-1272.	2.5	19
38	Liâ€“Fraumeni syndrome heterogeneity. Clinical and Translational Oncology, 2020, 22, 978-988.	2.4	18
39	A comparison of current neuroblastoma chemotherapeutics. Expert Opinion on Pharmacotherapy, 2004, 5, 71-80.	1.8	16
40	Clinical Features of Neuroblastoma with 11q Deletion: An Increase in Relapse Probabilities in Localized and 4S Stages. Scientific Reports, 2019, 9, 13806.	3.3	15
41	Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial. Cancers, 2018, 10, 387.	3.7	13
42	Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network. European Journal of Cancer, 2020, 135, 89-97.	2.8	13
43	Analysis of biological prognostic factors using tissue microarrays in neuroblastic tumors. Pediatric Blood and Cancer, 2009, 52, 209-214.	1.5	12
44	Review: Ewing Sarcoma Predisposition. Pathology and Oncology Research, 2020, 26, 2057-2066.	1.9	11
45	Metastatic neuroblastoma in infants: are survival rates excellent only within the stringent framework of clinical trials?. Clinical and Translational Oncology, 2017, 19, 76-83.	2.4	10
46	Minimal Residual Disease in Neuroblastoma: To GAGE or not to GAGE. Oncology Research, 2003, 14, 291-295.	1.5	9
47	MTHFR and VDR Polymorphisms Improve the Prognostic Value of MYCN Status on Overall Survival in Neuroblastoma Patients. International Journal of Molecular Sciences, 2020, 21, 2714.	4.1	9
48	Intra-Tumour Genetic Heterogeneity and Prognosis in High-Risk Neuroblastoma. Cancers, 2021, 13, 5173.	3.7	8
49	Tumour banks in pediatric oncology. Clinical and Translational Oncology, 2006, 8, 884-888.	2.4	7
50	Pharmacogenetics implementation in the clinics: information and guidelines for germline variants. , 2019, 2, 53-68.		7
51	Germline Predisposition to Pediatric Cancer, from Next Generation Sequencing to Medical Care. Cancers, 2021, 13, 5339.	3.7	7
52	Survey on paediatric tumour boards in Europe: current situation and results from the ExPo-r-Net project. Clinical and Translational Oncology, 2018, 20, 1046-1052.	2.4	4
53	Pharmacogenetics in Neuroblastoma: What Can Already Be Clinically Implemented and What Is Coming Next?. International Journal of Molecular Sciences, 2021, 22, 9815.	4.1	4
54	Immunoproteomic studies on paediatric opsoclonus-myoclonus associated with neuroblastoma. Journal of Neuroimmunology, 2016, 297, 98-102.	2.3	3

#	Article	IF	Citations
55	Paediatric tumour boards in Spain: a national survey. Clinical and Translational Oncology, 2016, 18, 931-936.	2.4	3
56	Imbalance between genomic gain and loss identifies high-risk neuroblastoma patients with worse outcomes. Neoplasia, 2021, 23, 12-20.	5.3	3
57	The new challenge in oncology: Next-generation sequencing and its application in precision medicine. Anales De PediatrÃa (English Edition), 2016, 85, 273.e1-273.e7.	0.2	2
58	Letter to the Editor. Clinical and Translational Oncology, 2018, 20, 1626-1627.	2.4	0